These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 23343427

  • 21. Economic evaluation of the antibiotic treatment of exacerbations of chronic bronchitis and COPD in primary care.
    Llor C, Naberan K, Cots JM, Molina J, Miravitlles M.
    Int J Clin Pract; 2004 Oct; 58(10):937-44. PubMed ID: 15587773
    [Abstract] [Full Text] [Related]

  • 22. Characterisation of patients receiving moxifloxacin for acute bacterial rhinosinusitis in clinical practice: results from an international, observational cohort study.
    Mösges R, Desrosiers M, Arvis P, Heldner S.
    PLoS One; 2013 Oct; 8(4):e61927. PubMed ID: 23626752
    [Abstract] [Full Text] [Related]

  • 23. Prulifloxacin versus levofloxacin in the treatment of severe COPD patients with acute exacerbations of chronic bronchitis.
    Blasi F, Schaberg T, Centanni S, Del Vecchio A, Rosignoli MT, Dionisio P.
    Pulm Pharmacol Ther; 2013 Oct; 26(5):609-16. PubMed ID: 23538168
    [Abstract] [Full Text] [Related]

  • 24. No more equivalence trials for antibiotics in exacerbations of COPD, please.
    Miravitlles M, Torres A.
    Chest; 2004 Mar; 125(3):811-3. PubMed ID: 15006934
    [No Abstract] [Full Text] [Related]

  • 25. Determining factors in the prescription of moxifloxacin in exacerbations of chronic bronchitis in the primary-care setting.
    Miravitlles M, Llor C.
    Clin Drug Investig; 2007 Mar; 27(2):95-104. PubMed ID: 17217314
    [Abstract] [Full Text] [Related]

  • 26. Efficacy and safety of sequential intravenous/oral moxifloxacin vs intravenous/oral amoxicillin/clavulanate for complicated skin and skin structure infections.
    Vick-Fragoso R, Hernández-Oliva G, Cruz-Alcázar J, Amábile-Cuevas CF, Arvis P, Reimnitz P, Bogner JR, STIC Study Group.
    Infection; 2009 Oct; 37(5):407-17. PubMed ID: 19768381
    [Abstract] [Full Text] [Related]

  • 27. Moxifloxacin: a review of its use in the management of bacterial infections.
    Keating GM, Scott LJ.
    Drugs; 2004 Oct; 64(20):2347-77. PubMed ID: 15456331
    [Abstract] [Full Text] [Related]

  • 28. Retrospective analysis of the safety profile of oral moxifloxacin in elderly patients enrolled in clinical trials.
    Andriole VT, Haverstock DC, Choudhri SH.
    Drug Saf; 2005 Oct; 28(5):443-52. PubMed ID: 15853445
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis.
    McDonald MB, Protzko EE, Brunner LS, Morris TW, Haas W, Paterno MR, Comstock TL, Usner DW.
    Ophthalmology; 2009 Sep; 116(9):1615-1623.e1. PubMed ID: 19643483
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Effect of ELOM-080 on exacerbations and symptoms in COPD patients with a chronic bronchitis phenotype - a post-hoc analysis of a randomized, double-blind, placebo-controlled clinical trial.
    Beeh KM, Beier J, Candler H, Wittig T.
    Int J Chron Obstruct Pulmon Dis; 2016 Sep; 11():2877-2884. PubMed ID: 27920515
    [Abstract] [Full Text] [Related]

  • 36. Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial.
    Rhee CK, Chang JH, Choi EG, Kim HK, Kwon YS, Kyung SY, Lee JH, Park MJ, Yoo KH, Oh YM.
    Int J Chron Obstruct Pulmon Dis; 2015 Sep; 10():2265-75. PubMed ID: 26543359
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. The efficacy of moxifloxacin in acute exacerbations of chronic bronchitis: a Spanish physician and patient experience.
    Miravitlles M, Ros F, Cobos A, Kubin R, Tillotson G.
    Int J Clin Pract; 2001 Sep; 55(7):437-41. PubMed ID: 11594251
    [Abstract] [Full Text] [Related]

  • 39. Efficacy and safety of short course (5-day) moxifloxacin vs 7-day ceftriaxone in the treatment of acute exacerbations of chronic bronchitis (AECB).
    Grassi C, Casali L, Curti E, Tellarini M, Lazzaro C, Schito G, SMART Study Group. Studio Multicentrico con Moxifloxacina nel Trattamento delle Riacutizzazioni de Bronchite Cronica.
    J Chemother; 2002 Dec; 14(6):597-608. PubMed ID: 12583552
    [Abstract] [Full Text] [Related]

  • 40. Moxifloxacin for the treatment of acute exacerbations of chronic obstructive pulmonary disease.
    Sethi S.
    Clin Infect Dis; 2005 Jul 15; 41 Suppl 2():S177-85. PubMed ID: 15942884
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.